Anastrozole Side Effects: From Joint Pain to Bone Loss

Anastrozole, prescribed mainly to postmenopausal women with hormone-receptor-positive breast cancer, works by blocking the enzyme that converts other hormones into estrogen. That near-complete estrogen suppression is what makes the drug effective against cancer, but it is also what drives the side effects. The most frequently reported problems are joint pain and stiffness, hot flashes, bone thinning, fatigue, and vaginal dryness. For most women, these are manageable enough to continue treatment, but they are common enough and disruptive enough that roughly one in ten women discontinues within the first few years.

Joint Pain and Musculoskeletal Symptoms

Joint aches are the side effect most likely to interfere with daily life and the single biggest reason women stop taking anastrozole early. The cluster of symptoms, sometimes called aromatase inhibitor-associated musculoskeletal syndrome, affects up to half of women on therapy and includes joint stiffness, general aches, and sometimes grip weakness or morning stiffness that takes a while to shake off. The pain commonly settles in the hands, wrists, knees, and ankles, and it tends to appear within the first few months of treatment.

One study tracking side-effect-related discontinuation found that about 10% of patients needed to stop their assigned aromatase inhibitor because of toxicity, and severe joint pain accounted for more than half of those cases.² In the first six weeks on anastrozole, the emergence of joint pain has been linked to a simultaneous uptick in fatigue, disturbed sleep, hot flashes, and vaginal dryness, suggesting that these symptoms tend to cluster rather than appear in isolation.³ The underlying cause is not fully worked out, but the prevailing theory is that sharp estrogen withdrawal affects both the musculoskeletal system and pain-processing pathways in the nervous system.⁴

Genetic factors may partly explain why some women are hit much harder than others. A systematic review found that variants in genes involved in estrogen signaling, specifically the estrogen receptor 1 gene and the CYP19A1 gene that encodes aromatase itself, were frequently associated with musculoskeletal symptoms.⁵ This research is still early-stage, but it hints at a future where a genetic test might help predict who will struggle most.

Bone Thinning and Fracture Risk

Estrogen is one of the main hormones that keeps bones from breaking down too fast. When anastrozole cuts estrogen levels to near zero, bone loss accelerates. A five-year analysis from the large ATAC trial confirmed that anastrozole causes accelerated bone loss throughout the treatment period.⁶ In a separate prospective study, women not given bone-protective medication lost over 5% of bone mineral density at the lumbar spine within the first year on anastrozole.⁷ That rate is several times faster than normal postmenopausal bone loss.

Fracture rates during active treatment were meaningfully higher with anastrozole than with tamoxifen in the ATAC trial. Importantly, that gap closed after treatment ended, suggesting that the accelerated loss is largely a feature of active estrogen suppression rather than permanent damage.⁸ For women already at risk of osteoporosis, though, the years of accelerated loss can be enough to tip them into fracture territory, which is why bone density monitoring is standard during treatment.

Hot Flashes, Sleep, and Fatigue

Hot flashes are common on anastrozole, though they are actually a bit less frequent than on tamoxifen. In the ATAC adjuvant trial, about 36% of women on anastrozole reported hot flashes compared to 41% on tamoxifen.⁹ That difference is real but modest, and 36% is still a lot of women dealing with a frustrating symptom.

What the trial numbers do not fully capture is how disruptive these episodes can be. A qualitative study of women on endocrine therapy found that hot flashes, particularly nocturnal ones, wreaked havoc on sleep. Women described being drenched in sweat, constantly tossing, and unable to sustain normal daytime functioning because of poor-quality rest. Some reported hot flashes striking every 10 to 15 minutes during the day, making even short stretches of normal activity difficult to sustain.¹⁰ Fatigue feeds into this cycle, and the cluster of symptoms together often ends up being more burdensome than any single one alone.

Sexual Health and Vaginal Symptoms

This is one of the most underreported areas of anastrozole side effects, partly because patients and clinicians alike can be reluctant to bring it up. Vaginal dryness, painful intercourse, and loss of sexual interest are significantly more common with anastrozole than with tamoxifen.¹¹ In one study of women in their first two years on an aromatase inhibitor, 93% scored in the dysfunctional range on a validated sexual function questionnaire, and roughly four out of five women who had been sexually active before treatment developed a new sexual problem.¹²

The broader umbrella term for these symptoms is genitourinary syndrome of menopause, which includes vaginal dryness, irritation, urinary urgency, and painful sex. It affects up to 60% of breast cancer survivors and tends to worsen rather than improve over time if left unaddressed.¹³ Because estrogen is the very hormone anastrozole is designed to suppress, treatment options require careful thought. A randomized trial found that ultra-low-dose vaginal estrogen improved vaginal dryness and painful intercourse with minimal absorption into the bloodstream, keeping serum estrogen levels low throughout the study.¹⁴ A separate trial using ultra-low-dose estriol vaginal gel also showed efficacy in relieving symptoms with minimal hormonal fluctuation.¹⁵ These options should be discussed with your oncologist, but the point is that vaginal symptoms are treatable and should not simply be endured in silence.

Cognitive Effects

Many women on anastrozole describe feeling foggy, forgetting words, or struggling to concentrate. The research paints a nuanced picture. One study tracking cognitive function over 18 months found that women starting anastrozole alone showed a measurable decline in visual working memory and concentration during the first six months, followed by improvement from six to 12 months, and then another dip around the 12-to-18-month mark. The effect sizes were small but consistent.¹⁶ Another study found that women receiving anastrozole had poorer verbal and visual learning and memory compared to those on tamoxifen.¹⁷

However, when anastrozole was compared against placebo in women without a cancer diagnosis who were taking it preventively, few women in either group reported memory or attention changes, and there was no difference between the drug and placebo groups at six or 24 months.¹⁸ That raises the possibility that some of the cognitive trouble attributed to anastrozole in cancer patients comes from the stress, anxiety, and sleep disruption of a cancer diagnosis rather than the drug alone. The honest answer is that anastrozole probably contributes to mild cognitive blunting in some women, but the effect is modest and often fluctuates over the course of treatment rather than steadily worsening.

Mood, Fatigue, and Hair Changes

Mood disturbance, anxiety, and depressive symptoms have been reported with anastrozole, though large trials have not flagged them as dramatically more common than with tamoxifen. A case report described a 56-year-old woman with no psychiatric history who developed severe mood changes after starting anastrozole that resolved once she stopped the drug.¹⁹ A longitudinal study tracking neuropsychiatric symptom burden found that on average, symptom scores nudged up slightly over 18 months, but the average masked very different trajectories. Some women had persistently low symptom levels throughout, while others started high and climbed further. Younger age and pre-existing use of antidepressants or anti-anxiety medications predicted being in a higher-burden group.²⁰

Hair thinning is another concern that receives less clinical attention than it deserves. It is typically mild, resembling a gradual pattern of thinning across the top of the scalp rather than the patchy or total hair loss associated with chemotherapy. In a study of over 100 patients with endocrine-therapy-related hair loss, about two-thirds of cases were attributed to aromatase inhibitors, and 93% were classified as mild (grade 1). More than half noticed thinning within the first year of treatment, though some did not notice it for years.²¹ Treatment options are limited and understudied.²²

Metabolic and Cardiovascular Effects

Estrogen helps regulate how the body handles insulin and stores fat, so suppressing it can shift metabolic parameters. A study of postmenopausal breast cancer patients on aromatase inhibitors found they were significantly more insulin resistant, had higher body fat percentage (about 38% vs. 35% in matched controls), and had higher leptin levels than similar women not on the drug.²³ A smaller study in healthy men given anastrozole also found reduced insulin sensitivity at lower insulin doses, though body weight and fat percentage did not change over the short study period.²⁴ These metabolic changes are worth knowing about, especially for women with existing risk factors for type 2 diabetes.

On the cholesterol front, the picture is less alarming than early concerns suggested. A meta-analysis of randomized trials found that anastrozole modestly lowered total cholesterol in shorter-term use, had no effect on LDL or triglycerides, and slightly reduced HDL with longer use.²⁵ A large population-based study looking primarily at letrozole users similarly concluded that aromatase inhibitor therapy does not appear to adversely affect lipid levels.²⁶ So while the metabolic effects on insulin and body composition are real, the lipid scare has largely not held up.

How Anastrozole Compares to Tamoxifen

If you are discussing treatment options with your oncologist, the side-effect profile differences between anastrozole and tamoxifen are worth understanding. The two drugs have different risk trade-offs rather than one being clearly worse than the other. In the ATAC trial, anastrozole caused fewer overall treatment-related adverse events and fewer serious adverse events than tamoxifen over nearly six years of follow-up.²⁷

But the types of side effects differed. Anastrozole was associated with more fractures, musculoskeletal complaints, and higher cholesterol, while tamoxifen was associated with more blood clots, gynecological symptoms, and hot flashes.²⁸ Tamoxifen also carries a small increased risk of endometrial cancer, which anastrozole does not. Overall, the 100-month ATAC analysis found that treatment-related serious adverse events were significantly less common with anastrozole, but that the fracture difference disappeared after treatment ended.²⁹ The choice often comes down to which set of risks matters more for your individual health profile.

Differences Between the Three Aromatase Inhibitors

Anastrozole and letrozole are structurally similar (both are nonsteroidal) while exemestane has a steroid-like structure that gives it mild androgenic activity. In theory, that androgenic effect could buffer some of the estrogen-deprivation symptoms, particularly bone loss and vaginal dryness.³⁰ In practice, the differences are subtle. A study examining a switch from anastrozole or letrozole to exemestane noted that while exemestane shows less bone toxicity than anastrozole, a significant difference across all menopausal symptoms has not been clearly demonstrated.³¹

A large study of treatment patterns found that discontinuation rates within five years were similar for anastrozole and letrozole (about 35% each) but somewhat higher for exemestane at around 39%.³² That may seem counterintuitive if exemestane’s androgenic properties are supposed to be protective, but real-world adherence is shaped by many factors beyond side-effect biology. For women who cannot tolerate anastrozole, switching to a different aromatase inhibitor is a common and reasonable strategy, and a meaningful number of women do better on the second drug even when the pharmacological differences are modest.

Protecting Your Bones During Treatment

Given the bone loss associated with anastrozole, bone-protective medications have been extensively studied. A meta-analysis of randomized trials found that zoledronic acid (given intravenously) improved bone mineral density at the lumbar spine by about 5% and the hip by about 4% relative to untreated controls over 12 months. Oral bisphosphonates offered a smaller but still meaningful benefit. Denosumab, a different type of bone-targeting injection, showed the strongest effect, improving lumbar spine density by about 6% and reducing fracture incidence by half compared to placebo.³³

A retrospective comparison of denosumab versus the oral bisphosphonate alendronate in women with aromatase-inhibitor-associated osteoporosis found that denosumab led to greater improvement in bone density and a lower rate of vertebral compression fractures.³⁴ These treatments are not given to every woman on anastrozole. Typically, your oncologist or endocrinologist will check your bone density at baseline and decide whether to start bone-protective therapy right away or monitor and intervene if density drops below a threshold. Weight-bearing exercise, adequate calcium, and vitamin D supplementation are broadly recommended alongside any pharmacological approach.

Rare Liver Effects

Anastrozole is overwhelmingly safe from a liver standpoint, but rare cases of drug-induced liver injury have been documented. A case report described a 58-year-old woman who developed significantly elevated liver enzymes four years into anastrozole treatment. No other medication or cause was identified, and her liver function returned to normal after stopping the drug. A review of the literature at the time identified only six prior reported cases.³⁵ The rarity of this complication means routine liver monitoring is not standard, but it is worth knowing about. If you develop unexplained nausea, abdominal pain, or yellowing of the skin while on anastrozole, mention the medication to whichever doctor you see.

What Predicts a Harder Time

Not every woman on anastrozole has the same experience, and some patterns have emerged in the research about who tends to have more trouble. Younger postmenopausal women generally report more severe side effects, particularly musculoskeletal and neuropsychiatric symptoms. This may be partly because younger women are experiencing a sharper drop from their baseline estrogen levels than older women whose levels were already lower. Women who were already taking antidepressants, pain medication, or anti-anxiety drugs before starting anastrozole were more likely to fall into the high neuropsychiatric burden groups in longitudinal tracking.³⁶

Body weight may also play a role, though not always in the direction you might expect. While higher BMI has been associated with less complete estrogen suppression with some aromatase inhibitors, the relationship with anastrozole specifically was not statistically significant in one study examining this question.³⁷ Still, carrying more body weight is associated with higher baseline estrogen levels in postmenopausal women (because fat tissue produces estrogen), which could theoretically influence both how well the drug works and how sharply side effects are felt. These are conversations worth having with your oncologist, who can weigh your individual risk factors against the substantial benefit anastrozole provides in reducing cancer recurrence.